NCT05023551View on ClinicalTrials.gov

Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 8, 2021

Primary Completion Date

September 30, 2026

Study Completion Date

October 31, 2026

Conditions
High Grade GliomaGlioblastoma Multiforme
Interventions
DRUG

DSP-0390

DSP-0390 administered orally

Trial Locations (9)

10032

Dana Farber Cancer Institute, Boston

Columbia University, New York

63110

Washington University School of Medicine, St Louis

84112

Huntsman Cancer Institute, University of Utah, Salt Lake City

94143

University of California at San Francisco, San Francisco

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

060-8648

Hokkaido University Hospital, Sapporo

606-8507

Kyoto University Hospital, Kyoto

104-0045

National Cancer Center Hospital, Chuo Ku

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY